CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Argenica Therapeutics Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Argenica Therapeutics Ltd
4/117 Broadway
Phone: +61 893293396p:+61 893293396 NEDLANDS, WAS  6009  Australia Ticker: AGNAGN
Business Summary
Argenica Therapeutics Limited is an Australia-based clinical drug development company. The Company is focused on developing therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. The Company's lead candidate, ARG-007, is a cationic arginine-rich peptide that aims to protect brain cells and reduce cell death following a stroke, and other types of neural injury, in order to minimize the impact of these conditions and improve patient recovery. ARG-007 has been successfully demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischaemic encephalopathy (HIE).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20236/30/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board DianneAngus 12/1/2023 12/1/2023
Chief Executive Officer, Managing Director, Executive Director LizDallimore 4/4/2022 3/21/2021
Company Secretary EmmaWaldon 11/20/2019 11/20/2019
3 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 99,150,822 (As of 12/31/2023)
Shareholders: 1,517
Stock Exchange: ASX


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 25, 2024